Presentation on theme: "Clinical Trials of Medicines in Ukraine"— Presentation transcript:
1Clinical Trials of Medicines in Ukraine Public Enterprise “The State Expert Centerof the Ministry of Health of Ukraine”Valentina NikolaievaPhD, Director of the Board of Preclinical and Clinical TrialsGreatest cities are Kiev, Kharkov, Dnepropetrovsk Donetsk Odessa, Lvov
2Ukraine Gained its independence in 1991 Situated in the central part of Eastern EuropeCapital – Kyiv (about 4 million)27 regionsPopulation – about 45 millionState language - UkrainianPrecise legislation: Constitution, Laws, Regulations, OrdersMore then Trial Sites with experience in CTGreatest cities are Kiev, Kharkov, Dnepropetrovsk Donetsk Odessa, Lvov
3The rules governing clinical trials (CTs) in Ukraine Law of Ukraine “On Medicines”Adopted in 1996Articles 7 and 8 regulate conducting of clinical trialsArt. 7 « Clinical trial of medicinal products»Clinical trials (CT) are conducted out:- at health care settings (HCSs);- if the positive results of the expert evaluation and assessment of the Ethics Committees at HCS are available;- MoH establishes procedure for conducting expert evaluation;- Ethics Committee (EC) are created and operate at HCSs;- decision to approve a CT protocol is accepted by central executive body for health or its authorized body
4The rules governing clinical trials (CTs) in Ukraine Orders of Ministry of Health of Ukraine which take into account requirements of:Council Directives 2001/20/EC, 2005/28 ECICH GCPDeclaration of HelsinkiWHO recommendations
5and Model Regulations of the Ethics Committees Regulations of CTsOrder of MoH Ukraine # 690 from in the wording of Order of MoH Ukraine # 523 from(Registered at the Ministry of Justice of Ukraine on under № 1235/21547 and № 1236/21548)Procedure for Conducting Clinical Trials of Medicinal Products and Expert Evaluation of Materials Pertinent to Clinical Trialsand Model Regulations of the Ethics Committees
6CPMP/ICH/135/95 (E 6) “Note for Guidance on Good Clinical Practice” Regulations of CTsCPMP/ICH/135/95 (E 6) “Note for Guidance on Good Clinical Practice”Order of MoH Ukraine # 95 from :Guidance “Medicinal Products. Good Clinical Practice ССТ-Н МОЗУ :2008”
7Regulations of CTsCPMP/EWP/QWP/1401/98 “Guideline on the Investigation of Bioequivalence”Order of MoH Ukraine # 191 from : Clinical Trials Guidance :2005 “Medicinal Products. Investigations of Bioavailability and Bioequivalence”Directive 2004/10/ЕСOrder of MoH Ukraine # 95 from Guidance “Medicinal Products. Good Laboratory practice”
8Regulations of CTs Methodological recommendations (99.12/190.12.): «Guideline on similar biological medicinal products» (CHMP/437/04/),«Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues» (EMEA/CHMP/BMWP/42832/2005),«Guideline on non-clinical and clinical development of similar biological medicinal products containing:low-molecular-weight-heparins EMEA/CHMP/BMWP/118264/2007)recombinant erythropoietins (Revision) (EMEA/CHMP/BMWP/301636/2008)recombinant human soluble insulin (EMEA/CHMP/BMWP/32775/2005)somatropin (EMEA/CHMP/BMWP/94528/2005)containing recombinant interferon alfa (EMEA/CHMP/BMWP/102046/2006)containing recombinant granulocyte-colony stimulating factor (EMEA/CHMP/BMWP/31329/2005)».Methodological recommendations (99.12/ ):The general principles of non-clinical and clinical issues on similar biological medicinal products containing biotechnology-derived proteins as active substance
9Regulations of CTsState Expert Centre of the Ministry of Health of Ukraine (SEC) has been authorized to regulate CTsMain tasks of SEC:Expertise of materials of CTsApproval CTsControl of CTs (Clinical audit / inspections)Monitoring SUSARControl of compliance of scientific research to the principles of biological and medical ethics
10PROCEDURE for Conducting CT of MP and Expert Evaluation of Materials of CT 14 chapters:GeneralDefinition of termsGeneral principles of conducting clinical trialsMain requirements to protection of subjectsRequirements to investigators and HCS/clinical trial siteThe main requirements to labeling of investigational medicinal productObtaining conclusion about expert evaluation of materials concerning a clinical trial of medicinal product (-s)Assessment of ethical, moral, and legal aspects of the clinical trialConducting a clinical trialChanges and additions during clinical trialTermination of clinical trialNotification of adverse events and reactionsClinical audit of clinical trials of medicinal productsSuspension or full stoppage of a clinical trial
11PROCEDURE for Conducting CT of MP and Expert Evaluation of Materials of CT 15 annexes:LIST OF MAIN DOCUMENTS PERTINENT TO CTCOVER LETTER (CT)APPLICATION FORM (CT)COMPLETE DOSSIER OF INVESTIGATIONAL MEDICINAL PRODUCTAPPLICATION OF PRINCIPAL INVESTIGATORINFORMATION ABOUT HEALTH CARE SETTING AND CLINICAL TRIAL SITENOTIFICATION ABOUT THE START OF CLINICAL TRIAL IN UKRAINELIST OF ASPECTS OF CLINICAL TRIAL WHICH MAY BE AMENDED SIGNIFICANTLY BY SPONSOR (LIST OF SIGNIFICANT AMENDMENTS)COVER LETTER (amendment)APPLICATION FORM (amendment)NOTIFICATION ABOUT COMPLETION OF CTPERIODICAL REPORT ON STATUS OF CTFORMAT OF FINAL CLINICAL TRIAL REPORTREQUIREMENTS TO NOTIFICATION ABOUT SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONREQUIREMENTS TO STRUCTURE OF UPDATE REPORT ABOUT SAFETY (DSUR)
12PROCEDURE for Conducting CT of MP and Expert Evaluation of Materials of CT General principles of clinical trialCT are conducted according to the ethical principles of the Declaration of HelsinkiCT are conducted at HCS determined by MoH based on the State Expert Center (SEC) positive conclusionPersons attracted to the performance of clinical trial should have appropriate education, proficiency and experience to perform their functions in CTSponsor is entrusted with a choice of investigatorsThe sponsor may delegate his powers to CRO, but is responsible for initiating CT and the data obtainedClinical trials shall be commenced when the Center’s positive conclusion approved by MoH, and positive assessment (minutes of the meeting) of the Ethics Committees at HCS are available
13PROCEDURE for Conducting CT of MP and Expert Evaluation of Materials of CT General principles of clinical trialEnsuring confidentialityCT are planned and conducted in compliance with GCPIf IMP is a narcotic one - compliance with relevant legislationSystem of procedures is used to ensure CT qualityCollection, processing and presentation of reliable dataData storage in HCS at least 15 yearsIMPs are produced according to GMPSEC may conduct clinical audit of CT
14Main requirements to conducting CTs Investigators and the applicant shall be governed by ICH GCP standardsFreely given informed consent should be obtained from every patient or his legal representative prior to participation in a clinical trial
15Approval of CTs by SEC Approval of amendments by SEC Order of MoH Ukraine # 523 from 12.07.2012 For conducting CTapplicant submit documents are subject to an expert evaluation at the SEC:Application (set form)CT protocolInvestigator’s brochureInformation for patients and informed consent formMain pages of CRFInsurance contractCertificate of analysis for batch of the IMP ...Approvals based on results of an expert evaluation of CT protocol / amendments
16The main stages of CT approval ApplicantApplicationCT materialsExpert evaluationSpecialized assessment of CT materials?Scientific and expert councilProtocols – 60 daysAmendments – 35 daysApproval of CT
17Ethical approval of CTs A favorable opinion by Local Ethics Committee is necessaryObligatory requirement to Ethics Committees - to act according to ICH GCP and Declaration of Helsinki
21Monitoring of Adverse Reactions during CTs Local Ethic CommitteeSystem of Immediate ReportingSAE immediatelyAccording to the ProtocolInvestigatorSponsorNo later 15 days SUSAR(7days – if death)Revealing of serious adverse events (SAEs)SECAdditionalinformation
22Monitoring of Adverse Reactions during CTs Periodic Safety Reporting Periodic reports on safety, at least once a yearSECSponsorUpdates of investigator’s brochure
23Monitoring of Adverse Reactions during CTs Taking of results into consideration during registration of medicinesRecording of ReportsCollecting of InformationAnalyzing of InformationSECTaking appropriate measures regarding CTs3 CT were stopped due to serious ADRs
24Notifications to be made by the responsible investigator/ investigator Order of MoH Ukraine # 523 fromNotification of adverse events and reactions (section XII to Procedure)Notifications to be made by the responsible investigator/ investigatorNotifications to be made by the sponsorICH Topic E2A «Clinical Safety Data Management: Definitions and Standards for Expedited Reporting», June 1995 (CPMP/ICH/377/95)ICH Topic E 6 (R1) Guideline for Good Clinical Practice, July 2002 CPMP/ICH/135/95Guidance EC «Communication from the Commission - Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use, 11 June (‘CT-3’) (2011/C 172/01)
25Order of MoH Ukraine # 523 from 12.07.2012 1. Notifications to be made by the responsible investigator / investigator:1.1. While conducting clinical trial the responsible investigator/investigator shall report all serious adverse events to the sponsor except for those that the protocol or investigator’s brochure identifies as such not requiring immediate reporting. The initial and follow-up reports shall identify subjects by unique code numbers assigned to them for the study.1.2. The responsible investigator/investigator shall also report the sponsor any adverse events and/or laboratory abnormalities identified in the clinical trial protocol as critical to safety evaluations according to the requirements and within the time periods specified by the sponsor in the protocol.
26continuanceNotifications to be made by the responsible investigator / investigator:1.3. The responsible investigator/investigator shall record immediately and within 7 calendar days after learning about this case all suspected unexpected serious adverse reactions associated with the investigational medicinal product which resulted in death or were life-threatening, to the ethics committee. The follow-up information on this case shall be given to the ethics committee within subsequent 8 calendar days. Requirements to the notification on a suspected unexpected serious adverse reaction are listed in Annex 14 to this Procedure.1.4. The responsible investigator/investigator shall inform the ethics committee about all other suspected unexpected serious adverse reactions associated with the investigational medicinal product which become known to him within 15 calendar days.1.5. In case of subject’s death the responsible investigator/investigator shall provide to the sponsor, the Center and the ethics committee any additional information requested by them.
272. Notifications to be made by the sponsor: Order of MoH Ukraine # 523 from2. Notifications to be made by the sponsor:2.1.Reporting the suspected unexpected serious adverse reactions to the Center (reporting period) begins from the date of approval by CEBHC of the Center’s conclusion on clinical trial and terminates with the end of clinical trial in Ukraine.2.2. The sponsor shall record immediately and within 7 calendar days after learning about such case report all suspected unexpected serious adverse reactions associated with the investigational medicinal product which resulted in death or were life-threatening to the Center. Relevant follow-up information on this case shall be given to the Center within subsequent 8 calendar days. Requirements to the notification on a suspected unexpected serious adverse reaction are listed in Annex 14 to this Procedure.2.3. The sponsor shall report to the Center all other serious unexpected adverse reactions associated with the investigational medicinal product which become known to him within 15 calendar days.2.4. The sponsor shall inform all responsible investigators/investigators who take part in the clinical trial of this investigational medicinal product concerned on all detected events capable of affecting subjects' safety.
28Notifications to be made by the sponsor: continuanceNotifications to be made by the sponsor:2.5. The sponsor shall keep documentation related to all adverse events the responsible investigators/investigators report to him.2.6. During long-term clinical trials the sponsor shall provide the Center a written report on the safety of the investigational medicinal product under development in paper and electronic format at least once a year, within 60 calendar days after preparation of the report according to the requirements stated in Annex 15 to this Procedure.In case of the substantiated suspicion on the increased risk for the subjects the Center may oblige the sponsor to submit safety report on the investigational medicinal product under development more frequently.2.7. In case of conducting several clinical trials of the same investigational medicinal product, the sponsor shall provide to the Center a single generalized report on the safety of investigational medicinal product. In a cover letter attached to the report the sponsor shall provide a listing of all clinical trials conducted in Ukraine or with Ukraine’s participation which are associated with this report. In this case the term of annual reporting begins from the date of receipt of the Center’s conclusion on the conduct of the first listed clinical trial.
29«Development Safety Update Report», September 2010 Order of MoH Ukraine # 523 fromREQUIREMENTS TO DEVELOPMENT SAFETY UPDATE REPORT ABOUT INVESTIGATIONAL MEDICINAL PRODUCT (Hereinafter-DSUR) (Annex 15 to Procedure)ICH guideline E2F«Development Safety Update Report», September 2010(EMA/CHMP/ICH/309348/2008 Committee for medicinal products for human use (CHMP)
30Order of MoH Ukraine # 523 from 12.07.2012 DSUR shall consist of 20 sections:1.Introduction.2.Worldwide authorization/registration status.3.Actions taken in the reporting period for safety reasons.4.Changes to reference safety information.5.Inventory of clinical trials ongoing and completed during the reporting period.6.Estimated cumulative exposure (overall effect):6.1.Cumulative exposure in the development program.6.2.Patient exposure (patient effect) from marketing experience.7.Data in line listings and summary tabulations:7.1.Reference information.7.2.Line listings of serious adverse reactions during the reporting period.7.3.Cumulative/summary tabulations of serious adverse events.
318.1.Completed clinical trials. 8.2.Ongoing clinical trials. continuance of Annex 158.Significant findings from clinical trials during the reporting period:8.1.Completed clinical trials.8.2.Ongoing clinical trials.8.3.Long-term control (follow-up).8.4.Other therapeutic use of investigational medicinal product.8.5.New safety data related to the combination therapies.9.Safety findings from non-interventional studies.10.Other clinical trial safety information.11.Safety findings from marketing experience.12.Non-clinical data.13.Literature.14.Other DSURs.15.Lack of efficacy.16.Region-specific information.17.Late-breaking information.18.Overall safety assessment:18.1.Evaluation of the risks.18.2.Benefit/risk considerations.19.Summary of important risks.20.Conclusions.
32SUSAR reports originating worldwide in clinical trials according to protocols approved or not approved in Ukraine and obtained by the Center
33SUSAR reports originating in Ukraine and received by the Center
34Inspections of Clinical trials (Clinical audit) Standard Operating ProceduresInspections cover all CTs including domestic and international CTsInspectors – specialists of SEC
35Main stages of inspection check-ups Order of MoH Ukraine # 523 fromSection XIII to ProcedureMain stages of inspection check-upsPreparing the planNotification of sponsor and investigatorsConducting inspection2001/20/EC2005/28/ECInvestigatorSponsorPositive conclusionFinal inspection report (Act)Detailed inspection reportNegative conclusionCritical remarksEssential remarksNon-essential remarksCT StoppedSECdata bank
36Inspections of Clinical Trials PerformanceRouting check-up during CT conductingRetrospective check-up after fulfillment CT based on archive dataTargeted check-up review of specific issues8 CT were stopped due toserious ADRsCritical Violation
37Import of registered and unregistered medicines, samples of placebo, related materials/export of biological samplesOrder of the Ministry of Health of Ukraine of №237 “On Approval of the Procedure for the Import of Unregistered Medicinal Products, Certified Reference Materials, and Reagents to the territory of Ukraine”— samples of substances for researches for conducting pre-clinical study;— investigational medicines, reference preparations, samples of placebo for clinical trials and research;— samples of medicines in pharmaceutical forms for registration;— finished medicines for exhibits at exhibitions, conferences, etc. without the right to sell;— finished medicines for individual use by citizens;— in cases of natural disasters, accidents, etc.;— import to the territory of Ukraine of reference medicines and/or substances, contaminants, biological standard preparations (substances comparison), the reference spectra and reagents for laboratory studies of drug quality.
40Issues in clinical trials The problem of taxToday, according to the Tax Code of Ukraine medicines imported for the purpose of clinical trials are subject to tax at 20%- This approach is contrary to the European regulatory practice and recommendations of the International Convention on the Simplification and Harmonization of Customs Procedures, which joined Ukraine in 2006- Factor taxation prevents the development of clinical trials and reduces investment attractiveness of UkraineThe exemption will increase the level of foreign investment of 1 billion UAH per year to 3 billion UAH per year over the next 2 years to 8 billion UAH a year over the next 4 years
41The present stage of CTs in Ukraine Adopted CTs regulationsTraining programsPublications:Periodical medical journals and other publicationsGuides on clinical trialsGuidelines on specific issues (organization CTs, statistic considerations, certain patient population: oncology, pulmonology, cardiology etc)
42Future of CTs in Ukraine Subsequent development of CTs regulations according to international requirementsTraining of investigators and specialists in the field of clinical trials organizationSpreading knowledge of GCP through seminars, conferences, publications